WebinarsSep 7, 2022How Memorial Hermann is Bringing Precision Healthcare to Texans with Population Genomics
Press ReleasesAug 29, 2022Anuva Announces Series A Closure and Enters Into a Strategic Partnership With Helix
NewsAug 29, 2022Helix recognized as "Top Genomics Company Accelerating Research and Discovery"San Diego Business Journal
Blog Advancing Cancer Care: Helix's New DPYD Testing for Safer ChemotherapyBy MD, FACP, FACMG Cassie Hajek, Medical Director at Helix
Press ReleasesHelix Expands Pharmacogenomic Test Portfolio to Support Safer Cancer and Alzheimer’s TreatmentsMay 28, 2025
Press ReleasesHelix Launches 23,000-Patient Clinico-Genomic Cohort for Autoimmune Diseases to Advance Drug Discovery and DevelopmentMarch 18, 2025
Press ReleasesHelix Unveils Groundbreaking Real-World Insights at the ACMG Annual Clinical Genetics Meeting, Driving Clinical Care ForwardMarch 13, 2025
VideosPartner Perspectives with Nebraska MedicineGenetic Insights Project helps Nebraskans take charge of their health
1Published ResearchIndividuals with PMS2 pathogenic variants are at average risk of cancer before age 60March 19, 2025
2Published ResearchScalable system-wide CYP2C19 pharmacogenomic testing reveals 38% excess incidence of adverse events in metabolizers receiving inappropriate prescriptionsMarch 19, 2025
3Published ResearchPopulation genomic screening leads to improved lipid management in patients with familial hypercholesterolemiaMarch 19, 2025
4Published ResearchUnderestimated risk of secondary complications in pathogenic and glucose-elevating GCK variant carriers with type 2 diabetesNovember 21, 2024
5Published ResearchA novel method for predicting Lp(a) levels from routine outpatient genomic testing identifies those at risk of cardiovascular disease across a diverse cohortNovember 4, 2024
